Dermatology

From a topical gene therapy to a debated heart failure option, a litany of unique agents are anticipated for FDA decision in the new year.

Sarina B. Elmariah, MD, PhD, talks about less commonly used treatments for patients with prurigo nodularis (PN).

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; provide an overview of therapies currently available for treating PN.

The approval for the non-surgical alternative was supported by phase 3 data showing ≥95% incidence eschar removal compared to a gel vehicle.

Allergic contact dermatitis burden many people, but it is important for patients to know why and how they may limit their risk.

A segment of an interview with Peter Young in which he describes his original interest in the subject of skincare product allergens.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; share guideline resources that physicians turn to when treating PN.

Experts in dermatology discuss treatment goals for PN and how they can differ based on severity of itching and nodules.

Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.

Dupilumab use surpassed all conventional systemic drug use since its introduction in 2017 until the end of the study in 2020-21.

Research on patients with generalized pustular psoriasis or erythrodermic psoriasis showed positive results for risankizumab.

A recent study highlighted psoriasis patients' lack of awareness of a link between psoriasis and obesity, as well as these same patients' hopes for future treatment programs targeting weight loss.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, share the importance of having multiple health care providers across the disciplines when diagnosing and treating prurigo nodularis (PN).

Experts in dermatology examine a patient’s road to diagnosis of prurigo nodularis (PN), focusing on the symptoms that bring them to the initial specialist visit.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss the pathophysiology on PN and the role of type 1 inflammation in the disease.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, provide an overview of prurigo nodularis (PN), its prevalence, and how it is a unique disease state to be differentiated from other disorders.

Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.

Why patience is key following the major FDA decision earlier this year.

An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.

A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

A discussion with Dr. Orozco on her SDPA 2022 presentation, discussing useful resources for physicians and PAs looking to get involved in the PAs Go Beyond campaign.

Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.